CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
lenalidomidedrug
Likely dose
lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00717756
NCT00717756Phase 2Completed
CompareCT.gov

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Brown University·interventional·Posted Jul 17, 2008·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating lenalidomide for Liver Cancer. Completed, enrolled 41 participants across 3 sites.

Detailed Summary

This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesUnited States
CollaboratorsMemorial Hospital of Rhode Island, Roger Williams Medical Center

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 17, 2008
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.0 years ago

Interventions

lenalidomidedrug

25 mg po qd x 21 days then 1 week off equals one cycle